RT Journal Article
SR Electronic
T1 COVID-19 induces a hyperactive phenotype in circulating platelets
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.24.20156240
DO 10.1101/2020.07.24.20156240
A1 Comer, Shane P.
A1 Cullivan, Sarah
A1 Szklanna, Paulina B.
A1 Weiss, Luisa
A1 Cullen, Steven
A1 Kelliher, Sarah
A1 Smolenski, Albert
A1 Moran, Niamh
A1 Murphy, Claire
A1 Altaie, Haidar
A1 Curran, John
A1 O’Reilly, Katherine
A1 Marsh, Brian
A1 Gaine, Sean
A1 McCullagh, Brian
A1 Ní Áinle, Fionnuala
A1 Kevane, Barry
A1 Maguire, Patricia B.
A1 On behalf of the COCOON Study investigators
YR 2020
UL http://medrxiv.org/content/early/2020/07/26/2020.07.24.20156240.abstract
AB Background Coronavirus disease 2019 (COVID-19), caused by novel coronavirus SARS-CoV-2, has to date affected over 13.3 million globally. Although high rates of venous thromboembolism and evidence of COVID-19-induced endothelial dysfunction have been reported, the precise aetiology of the increased thrombotic risk associated with COVID-19 infection remains to be fully elucidated.Objectives Here, we assessed clinical platelet parameters and circulating platelet activity in patients with severe and non-severe COVID-19.Methods An assessment of clinical blood parameters in patients with severe COVID-19 disease (requiring intensive care), patients with non-severe disease (not requiring intensive care), general medical in-patients without COVID-19 and healthy donors was undertaken. Platelet function and activity were also assessed by secretion and specific marker analysis.Results We show that routine clinical blood parameters including increased MPV and decreased platelet:neutrophil ratio are associated with disease severity in COVID-19 upon hospitalisation and intensive care unit admission. Strikingly, agonist-induced ADP release was dramatically higher in COVID-19 patients compared with non-COVID-19 hospitalized patients and circulating levels of PF4, sP-selectin and TPO were also significantly elevated in COVID-19.Conclusion Distinct differences exist in routine full blood count and other clinical laboratory parameters between patients with severe and non-severe COVID-19. Moreover, we have determined that COVID-19 patients possess hyperactive circulating platelets. These data suggest that abnormal platelet reactivity may contribute to hypercoagulability in COVID-19. Further investigation of platelet function in COVID-19 may provide additional insights into the aetiology of thrombotic risk in this disease and may contribute to the optimisation of thrombosis prevention and treatment strategies.Key FindingsRoutine platelet-related clinical blood parameters (MPV, PNR) are associated with disease severity in COVID-19.Agonist-induced ADP release is dramatically higher in COVID-19 patients compared with non-COVID-19 hospitalized patients.Circulating levels of PF4, sP-selectin levels and TPO are significantly elevated in COVID-19.Identification of a hyperactive platelet phenotype may warrant re-evaluation of current thrombotic prevention strategies in COVID-19 treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funding from Science Foundation Ireland (COVID-19 Rapid Response; 20/COV/0157).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval to proceed with this study (1/378/2077) was granted by the Institutional Review Board of the Mater Misericordiae University Hospital.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data, analytic methods and study materials supporting the findings of this study are provided in the manuscript, supplementary material and available from the corresponding authors upon reasonable request.